keyword
MENU ▼
Read by QxMD icon Read
search

Stage IV lung cancer

keyword
https://www.readbyqxmd.com/read/27901246/chemotherapy-for-advanced-non-small-cell-lung-cancer-in-the-elderly-population
#1
Fábio Nasser Santos, Tiago Biachi de Castria, Marcelo Rocha Souza Cruz, Rachel Riera
BACKGROUND: Approximately 50% of patients with newly diagnosed non-small cell lung cancer (NSCLC) are over 70 years of age at diagnosis. Despite this fact, these patients are underrepresented in randomized controlled trials (RCTs). As a consequence, the most appropriate regimens for these patients are controversial, and the role of single-agent or combination therapy is unclear. In this setting, a critical systematic review of RCTs in this group of patients is warranted. OBJECTIVES: To assess the effectiveness and safety of different cytotoxic chemotherapy regimens for previously untreated elderly patients with advanced (stage IIIB and IV) NSCLC...
September 2016: São Paulo Medical Journal, Revista Paulista de Medicina
https://www.readbyqxmd.com/read/27901003/fibroblast-growth-factor-receptor-1-gene-amplification-in-nonsmall-cell-lung-cancer
#2
REVIEW
Jian-Long Miao, Rui-Juan Liu, Jin-Hua Zhou, Shu-Hua Meng
OBJECTIVE: To review the prevalence and prognostic significance of fibroblast growth factor receptor 1 (FGFR1) amplification and to establish an association between FGFR1 amplification and the clinical characteristics of nonsmall cell lung cancer (NSCLC). DATA SOURCES: We searched PubMed for English-language studies published between January 2010 and May 2016. STUDY SELECTION: We included all relevant articles, with no limitation of study design...
2016: Chinese Medical Journal
https://www.readbyqxmd.com/read/27894601/treatment-rationale-and-study-design-for-the-relay-study-a-multicenter-randomized-double-blind-study-of-erlotinib-with-ramucirumab-or-placebo-in-patients-with-epidermal-growth-factor-receptor-mutation-positive-metastatic-non-small-cell-lung-cancer
#3
Edward B Garon, Martin Reck, Luis Paz-Ares, Santiago Ponce, Jesus Corral Jaime, Oscar Juan, Ernest Nadal, Pablo Lee, Rita Dalal, Jingyi Liu, Shuang He, Joseph Treat, Kazuhiko Nakagawa
INTRODUCTION: We present the treatment rationale and study design for the RELAY study (NCT02411448 ). This phase Ib/III study will assess safety, tolerability, and efficacy of the combination of ramucirumab with erlotinib in previously untreated stage IV non-small-cell lung cancer patients with an activating epidermal growth factor receptor (EGFR) mutation. PATIENTS AND METHODS: The study is being conducted in approximately 120 sites in North America, Europe, and Asia and is currently open for enrollment...
June 8, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/27894221/effectiveness-and-safety-of-pemetrexed-for-non-small-cell-lung-cancer-in-the-andalusian-public-health-system
#4
María Antonia Pérez-Moreno, Jesús Cotrina-Luque, Mercedes Galván-Banqueri, Sandra Flores-Moreno, Francisco Javier Bautista-Paloma, Miguel Ángel Calleja-Hernández
OBJECTIVE: To evaluate effectiveness and safety profile of pemetrexed in patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) when it´s used on real clinical practice in Andalusia (a Spanish region with 8.5 million inhabitants, 2014 census data). METHODS: An observational multicentre retrospective study was conducted. Adult patients with locally advanced/metastatic NSCLC who received pemetrexed in any hospital in the Andalusian Public Health System during the last term of 2011 were included...
November 1, 2016: Farmacia Hospitalaria
https://www.readbyqxmd.com/read/27893326/randomized-prospective-biomarker-trial-of-ercc1-for-comparing-platinum-and-nonplatinum-therapy-in-advanced-non-small-cell-lung-cancer-ercc1-trial-et
#5
Siow Ming Lee, Mary Falzon, Fiona Blackhall, James Spicer, Marianne Nicolson, Abhro Chaudhuri, Gary Middleton, Samreen Ahmed, Jonathan Hicks, Barbara Crosse, Mark Napier, Julian M Singer, David Ferry, Conrad Lewanski, Martin Forster, Sally-Ann Rolls, Arrigo Capitanio, Robin Rudd, Natasha Iles, Yenting Ngai, Michael Gandy, Rachel Lillywhite, Allan Hackshaw
Purpose Retrospective studies indicate that expression of excision repair cross complementing group 1 (ERCC1) protein is associated with platinum resistance and survival in non-small-cell lung cancer (NSCLC). We conducted the first randomized trial, to our knowledge, to evaluate ERCC1 prospectively and to assess the superiority of nonplatinum therapy over platinum doublet therapy for ERCC1-positive NSCLC as well as noninferiority for ERCC1-negative NSCLC. Patients and Methods This trial had a marker-by-treatment interaction phase III design, with ERCC1 (8F1 antibody) status as a randomization stratification factor...
November 28, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27884772/ovol2-gene-inhibits-the-epithelial-to-mesenchymal-transition-in-lung-adenocarcinoma-by-transcriptionally-repressing-twist1
#6
Zhi-Hai Wang, Zhong Li, Meng Hu, Qing-Jie Yang, Shen Yan, Rong-Si Wu, Bo-An Li, Ming Guo
BACKGROUND: Associated with recent achievements in therapy for advanced lung adenocarcinoma, there will still be an unmet medical need for effective treatment of stage IIIb/IV, and the prognosis of lung cancer is not optimistic till now. OBJECTIVE: In order to obtain some essential evidences for a potential targeted therapy in lung adenocarcinoma, the effects of Ovol2 gene on Epithelial-to-Mesenchymal Transition (EMT) was observed and the probable mechanisms were analyzed...
November 21, 2016: Gene
https://www.readbyqxmd.com/read/27877007/further-understanding-of-an-uncommon-disease-of-combined-small-cell-lung-cancer-clinical-features-and-prognostic-factors-of-114-cases
#7
Yu Men, Zhouguang Hui, Jun Liang, Qinfu Feng, Dongfu Chen, Hongxing Zhang, Zefen Xiao, Zongmei Zhou, Weibo Yin, Luhua Wang
OBJECTIVE: Combined small cell lung cancer (C-SCLC) is an uncommon subgroup of small cell lung cancer (SCLC) and few clinical data can be referred. Our study is to investigate the clinical features and prognostic factors of C-SCLC, as well as the role of multimodality treatment. METHODS: Between January 2004 and December 2012, patients with histologically diagnosed C-SCLC were retrospectively analyzed. The survivals were evaluated with the Kaplan-Meier method. Univariate and multivariate analyses were used to evaluate potential prognostic factors...
October 2016: Chinese Journal of Cancer Research, Chung-kuo Yen Cheng Yen Chiu
https://www.readbyqxmd.com/read/27875523/a-protein-fragment-derived-from-dna-topoisomerase-i-as-a-novel-tumour-associated-antigen-for-the-detection-of-early-stage-carcinoma
#8
Shang-Mian Yie, Shang-Rong Ye, Xiao-Li Ma, Ke Xie, Jian-Bo Zhang, Mei Cao, Xu He, Zhen-Bo Hu, Cheng-Lu Yang, Jia Zhang, Jie Zeng
BACKGROUND: The production of autoantibodies against tumour-associated antigens (TAAs) is believed to reflect greater immunologic reactivity in cancer patients and enhanced immune surveillance for cancer cells. Over the past few decades, a number of different TAAs and their corresponding autoantibodies have been investigated. However, positive frequency of autoantibody detection in cancer patients has been relatively low. Here we describe a novel TAA that was a fragment derived from human DNA-topoiomerase I and an autoantibody against the novel TAA with relatively high positive frequency in the sera of early-stage non-small-cell lung cancer (NSCLC), gastric cancer (GC), colorectal cancer (CRC) and oesophageal squamous cell carcinoma (ESCC)...
November 22, 2016: British Journal of Cancer
https://www.readbyqxmd.com/read/27871270/might-radiation-therapy-in-addition-to-chemotherapy-improve-overall-survival-of-patients-with-non-oligometastatic-stage-iv-non-small-cell-lung-cancer-secondary-analysis-of-two-prospective-studies
#9
ShengFa Su, YinXiang Hu, WeiWei Ouyang, Zhu Ma, QingSong Li, HuiQin Li, Yu Wang, XiaoHu Wang, Tao Li, JianCheng Li, Ming Chen, You Lu, YuJu Bai, ZhiXu He, Bing Lu
BACKGROUND: The role of radiation therapy in addition to chemotherapy has not been well established in non-oligometastatic Stage IV non-small cell lung cancer (NSCLC). We aimed to investigate overall survival (OS) of non-oligometastatic Stage IV NSCLC treated with chemotherapy with concurrent radiation to the primary tumor. METHODS: Eligible patients were screened from two prospective studies. Oligometastatic and non-oligometastatic NSCLC were defined as having < 5 and ≥5 metastatic lesions, respectively...
November 21, 2016: BMC Cancer
https://www.readbyqxmd.com/read/27867747/early-diagnosis-of-genital-mucosal-melanoma-how-good-are-our-dermoscopic-criteria
#10
Tova Rogers, Melissa Pulitzer, Maria L Marino, Ashfaq A Marghoob, Oliver Zivanovic, Michael A Marchetti
BACKGROUND: There are limited studies on the dermoscopic features of mucosal melanoma, particularly early-stage lesions. Described criteria include the presence of blue, gray, or white colors, with a reported sensitivity of 100%. It is unclear if these features will aid in the detection of early mucosal melanoma or improve diagnostic accuracy compared to naked-eye examination alone. CASE: An Asian female in her fifties was referred for evaluation of an asymptomatic, irregularly pigmented patch of the clitoral hood and labia minora of unknown duration...
October 2016: Dermatology Practical & Conceptual
https://www.readbyqxmd.com/read/27867003/prognostic-impact-of-newly-proposed-m-descriptors-in-tnm-classification-of-non-small-cell-lung-cancer
#11
Junghoon Shin, Bhumsuk Keam, Miso Kim, Young Sik Park, Tae Min Kim, Dong-Wan Kim, Young Whan Kim, Dae Seog Heo
INTRODUCTION: The International Association for the Study of Lung Cancer recently proposed new M descriptors for the next edition of the TNM classification for NSCLC, subdividing the current M1b category into two subcategories: M1b, which indicates a solitary extrathoracic metastasis in a single organ, and M1c, which indicates multiple extrathoracic metastasis. The purpose of this study was to validate the prognostic value of the newly proposed M descriptors in an independent cohort with multivariate and subgroup analysis...
November 17, 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27865625/second-line-treatment-selection-in-patients-with-non-small-cell-lung-cancer-of-adenocarcinoma-histology-findings-from-a-european-survey-of-treating-physicians
#12
Nicolas Girard, Jesus Corral, Diego Cortinovis, David F Heigener
BACKGROUND: Guidelines provide treatment recommendations for advanced non-small-cell lung cancer (NSCLC), but physicians must also consider other factors. We surveyed physicians treating NSCLC to determine their therapy goals, drivers of treatment choice, current prescribing behavior, and therapy expectations. MATERIALS AND METHODS: In 2015, an online survey was conducted of 500 pulmonologists/oncologists treating lung adenocarcinoma in Germany, France, Italy, Spain, and the United Kingdom, comprising screening and therapy decision questions...
October 26, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/27863923/pretreatment-red-blood-cell-total-folate-concentration-is-associated-with-response-to-pemetrexed-in-stage-iv-nonsquamous-non-small-cell-lung-cancer
#13
Stephen J Bagley, Steven Vitale, Suhong Zhang, Charu Aggarwal, Tracey L Evans, Evan W Alley, Roger B Cohen, Corey J Langer, Ian A Blair, Anil Vachani, Alexander S Whitehead
INTRODUCTION: Pemetrexed inhibits folate-dependent enzymes involved in pyrimidine and purine synthesis. Previous studies of genetic variation in these enzymes as predictors of pemetrexed efficacy have yielded inconsistent results. We investigated whether red blood cell (RBC) total folate, a phenotypic rather than genotypic, marker of cellular folate status was associated with the response to pemetrexed-based chemotherapy in advanced nonsquamous non-small-cell lung cancer (NSCLC). MATERIALS AND METHODS: We conducted a prospective cohort study of patients with stage IV nonsquamous NSCLC receiving first-line chemotherapy containing pemetrexed...
October 26, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/27863731/pulmonary-resection-for-synchronous-m1b-cstage-iv-non-small-cell-lung-cancer%C3%A2-patients
#14
Masafumi Yamaguchi, Makoto Edagawa, Yuzo Suzuki, Ryo Toyozawa, Fumihiko Hirai, Kaname Nosaki, Takashi Seto, Mitsuhiro Takenoyama, Yukito Ichinose
BACKGROUND: We wanted to assess the efficacy of curative intent pulmonary resection for non-small cell lung cancer (NSCLC) patients with synchronous M1b-distant metastases in a single organ or lesion. METHODS: Between 1995 and 2015, 23 consecutive synchronous M1b-cStage IV NSCLC patients who underwent any treatment for metastases and curative intent pulmonary resection were retrospectively analyzed. RESULTS: Sixteen patients were men and 7 were women, with a median age of 56 years (range: 41 to 76 years)...
November 15, 2016: Annals of Thoracic Surgery
https://www.readbyqxmd.com/read/27863497/next-generation-sequencing-facilitates-detection-of-the-classic-e13-a20-eml4-alk-fusion-in-an-alk-fish-ihc-inconclusive-biopsy-of-a-stage-iv-lung-cancer-patient-a-case-report
#15
Anna-Lena Volckmar, Volker Endris, Farastuk Bozorgmehr, Clemens Lier, Carlota Porcel, Martina Kirchner, Jonas Leichsenring, Roland Penzel, Michael Thomas, Peter Schirmacher, Arne Warth, Albrecht Stenzinger
BACKGROUND: Inhibition of the oncogenic fusion-gene EML4-ALK is a current first-line approach for patients with stage IV non-small cell lung cancer. While FISH was established as the gold standard for identifying these patients, there is accumulating evidence that other methods of detection, i.e., immunohistochemistry and next-generation sequencing (NGS), exist that may be equally successful. However, the concordance of these methods is under investigation. CASE PRESENTATION: Adding to the current literature, we here report a 56 year old female never-smoker with stage IV lung adenocarcinoma whose biopsy was IHC and FISH inconclusive but positive in NGS...
November 18, 2016: Diagnostic Pathology
https://www.readbyqxmd.com/read/27856142/efficacy-and-safety-of-onartuzumab-in-combination-with-first-line-bevacizumab-or-pemetrexed-based-chemotherapy-regimens-in-advanced-non-squamous-non-small-cell-lung-cancer
#16
Heather Wakelee, Zanete Zvirbule, Filippo De Braud, C Daniel Kingsley, Tarek Mekhail, Thomas Lowe, Wolfgang Schütte, Hervé Lena, William Lawler, Fadi Braiteh, Thomas Cosgriff, Diego Kaen, Michelle Boyer, Jessie Hsu, See Phan, Silvia Novello
BACKGROUND: Onartuzumab is a monovalent monoclonal antibody that binds with the extracellular domain of the MET receptor. Given the role of MET in non-small-cell lung cancer (NSCLC), we investigated whether onartuzumab added to first-line chemotherapy efficacy in non-squamous NSCLC. METHODS: Patients with untreated stage IIIB/IV non-squamous NSCLC, stratified by MET diagnostic status, were randomized to receive onartuzumab (15 mg/kg intravenously every 3 weeks) or placebo in combination with either paclitaxel/platinum/bevacizumab (bevacizumab cohort), or in combination with platinum/pemetrexed (pemetrexed cohort) with maintenance bevacizumab or pemetrexed and onartuzumab/placebo as appropriate...
October 19, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/27852063/depression-induces-poor-prognosis-associates-with-the-down-regulation-brain-derived-neurotrophic-factor-of-serum-in-advanced-small-cell-lung-cancer
#17
Yufeng Wu, Ruirui Si, Sen Yang, Suhua Xia, Zelai He, Lili Wang, Zhen He, Qiming Wang, Hong Tang
Patients with lung cancer often experience a state of depression, and these conditions may severely affect their quality of life (QoL) and prescription compliance. The current study was conducted to delineate the complex links between depression and the prognosis of patients with small cell lung cancer (SCLC) and the underlying mechanism was also explored.186 patients who received platinum-based chemotherapy for newly diagnosed stage III or stage IV SCLC were enrolled. The Self-Rating Depression Scale (SDS) questionnaire was completed the day before the start of chemotherapy to assess the depression status of the patients...
November 11, 2016: Oncotarget
https://www.readbyqxmd.com/read/27843609/novel-prognostic-prediction-models-for-patients-with-stage-iv-colorectal-cancer-after-concurrent-curative-resection
#18
N Miyoshi, M Ohue, M Yasui, S Noura, T Shingai, K Sugimura, H Akita, K Gotoh, S Marubashi, H Takahashi, J Okami, Y Fujiwara, M Higashiyama, M Yano
BACKGROUND: We developed a prediction tool for recurrence and survival in patients with stage IV colorectal cancer (CRC) following surgically curative resection. PATIENTS AND METHODS: From January 1983 to December 2012, 113 patients with CRC and synchronous liver and/or lung metastatic CRC were investigated at the Osaka Medical Center for Cancer and Cardiovascular Diseases. All patients underwent curative resection of primary and metastatic lesions. In the group of patients who underwent surgery from 1983 to 2008, a Cox regression model was used to develop prediction models for 1-year, 3-year and 5-year cancer-specific survival (CSS) and relapse-free survival (RFS)...
2016: ESMO Open
https://www.readbyqxmd.com/read/27842505/the-prognostic-value-of-serum-ca-19-9-for-patients-with-advanced-lung-adenocarcinoma
#19
Yuki Sato, Daichi Fujimoto, Keiichiro Uehara, Ryoko Shimizu, Jiro Ito, Mariko Kogo, Shunsuke Teraoka, Ryoji Kato, Kazuma Nagata, Atsushi Nakagawa, Kojiro Otsuka, Hiroshi Hamakawa, Yutaka Takahashi, Yukihiro Imai, Keisuke Tomii
BACKGROUND: This study aimed to assess the prognostic accuracy of serum CA 19-9 in patients with advanced lung adenocarcinoma. METHODS: We retrospectively reviewed data of 246 patients who were diagnosed at our institute with advanced (stage IIIB or IV) lung adenocarcinoma between March 2006 and December 2012. We excluded patients who received no chemotherapy, or for whom we had no data on pre-treatment tumor markers. We also evaluated 116 consecutive resected specimens from patients with clinical stage I lung adenocarcinoma pathologically...
November 14, 2016: BMC Cancer
https://www.readbyqxmd.com/read/27832654/predictive-and-prognostic-value-of-early-disease-progression-by-pet-evaluation-in-advanced-non-small-cell-lung-cancer
#20
Giuseppe Luigi Banna, Giuseppe Anile, Giorgio Russo, Paolo Vigneri, Marine Castaing, Maurizio Nicolosi, Salvatore Strano, Stefania Gieri, Rosaria Spina, Domenico Patanè, Giacomo Calcara, Filippo Fraggetta, Francesco Marletta, Alessandro Stefano, Massimo Ippolito
OBJECTIVE: To assess the predictive and prognostic value of progressive metabolic disease (PMD) by the use of early 18Fluorodeoxyglucose positron emission tomography (18FDG-PET) in patients with clinical stage IV non-small cell lung cancer (NSCLC) treated with first-line chemotherapy. METHODS: An 18FDG-PET performed following the first cycle of chemotherapy (PET-1) was compared with a pretreatment 18FDG-PET (PET-0) and a computed tomography (CT) scan after the third cycle (CT-3)...
November 11, 2016: Oncology
keyword
keyword
41253
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"